Main > ONCOLOGY (**) > Breast Cancer>HR+>HER2->MET>PIK3CA- > TREAT.: > CH. N. Alpelisib+Fulvestrant
CH. N. Alpelisib+Fulvestrant's subsections
(*) CA Approval Date: 2020. 08.13.
(*) EU CE Mark Date: 2020. 07.29
(*) USA Approval Date: 2019. 05.24.
>Endocrine-based regimen
Companion Diagnostics>
Company
Kinase Inhibitor
Patent(*)>Assignee; Claims; No.; Et
Patent>Total USA No.: 3
Patent>UpDate: 2019. 12.31.
RTM
RTM Web-Site
CH. N. Alpelisib+Fulvestrant's products
This section has no products